News

May 27, 2020
Pneumagen Announces £4m fundraising and Commits to Clinical Trial Development for COVID-19
May 8, 2020
Pneumagen Ltd’s Recent COVID-19 Data Covered by BBC’s "The Nine"
Apr 28, 2020
Pneumagen Ltd Announces Positive Anti–Viral Activity for Novel Glycan Approach in Preventing COVID–19 Infections
Mar 17, 2020
Pneumagen Ltd Leverages its Novel Glycan Approach to Target Coronavirus (COVID-19) Infections
Nov 12, 2019
Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019
Oct 15, 2019
Pneumagen Demonstrates Preclinical Proof-of-Concept in Oncology for Neumonco, a Novel Carbohydrate Binding Module
Sep 10, 2019
Pneumagen Demonstrates Preclinical Proof-of-Concept for Neumifil™ in Respiratory Syncytial Virus Infections
Aug 28, 2019
Pneumagen Appoints Scientific Advisory Board
Mar 1, 2015
Publication - Sialic Acid-Binding Protein Sp2CBMTD Protects Mice against Lethal Challenge with Emerging Influenza A (H7N9) Virus
Mar 6, 2014
PUBLICATION - Prevention of influenza by targeting host receptors using engineered proteins